Multiple Myeloma

MULTIPLE MYELOMA ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021

Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
NCI-MATCH Trial Identifies Actionable Alterations in More Than One-Third of Patients With Cancer

Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.
Targeted Therapies, Immunotherapies, Immunomodulators: A Quick Guide to Cancer Therapy Descriptions

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
Multicenter Study of Spanish Patients Provides New Insights on COVID-19 in Multiple Myeloma

In addition to age, sex, and comorbidities, a new study flagged uncontrolled cancer and renal insufficiency as key prognostic factors for COVID-19 outcomes.
A Look at DARZALEX^® (daratumumab) Treatment Regimen in Newly Diagnosed Multiple Myeloma Patients Who are Transplant Eligible

DARZALEX® is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma.

VIDEO SERIES

The Potential of Immunotherapy

ASH: Clinical Insights

Pre-transplantation Treatments

Daratumumab: A New Standard

Approaching Relapses After Treatment

Adherence to Medications

Treating Elderly Patients

Myeloma: Future Treatments

Mechanisms of Resistance

MULTIPLE MYELOMA NEWS

CD33 positivity and MPC-1 negativity appear to be associated with worse outcomes in patients with multiple myeloma treated with bortezomib as induction therapy.

Study Finds Low Adherence to Lenalidomide Therapy in Multiple Myeloma

January 13, 2021

A blood smear of chronic myeloid leukemia cells.

PARP Inhibition Associated With Increased Risk for Secondary MDS, AML

January 13, 2021

Pegylated Interferon Controlled Extreme Thrombocytosis, Well-Tolerated in Younger Patients With MPN

January 12, 2021

A close shot of a clinician injecting a drug into a patient's arm.

Effects of Daratumumab on Patient-Reported Outcomes, HRQOL in Newly Diagnosed Multiple Myeloma

January 8, 2021

Pathologist examining test tube samples in lab.

Laboratory Markers Found to Correlate With Symptom Burden in Relapsed/Refractory Multiple Myeloma

January 6, 2021

Next post in Multiple Myeloma

A blood smear of chronic myeloid leukemia cells.

PARP Inhibition Associated With Increased Risk for Secondary MDS, AML